- Home
- ACAD vs SEE Comparison
ACAD vs SEE Comparison
Compare ACAD & SEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SEE
- Stock Information
- Founded
- ACAD 1993
- SEE 1960
- Country
- ACAD United States
- SEE United States
- Employees
- ACAD N/A
- SEE N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SEE Major Chemicals
- Sector
- ACAD Health Care
- SEE Industrials
- Exchange
- ACAD Nasdaq
- SEE Nasdaq
- Market Cap
- ACAD 4.0B
- SEE 4.6B
- IPO Year
- ACAD 2004
- SEE N/A
- Fundamental
- Price
- ACAD $25.99
- SEE $32.23
- Analyst Decision
- ACAD Buy
- SEE
- Analyst Count
- ACAD 20
- SEE 0
- Target Price
- ACAD $28.63
- SEE N/A
- AVG Volume (30 Days)
- ACAD 2.0M
- SEE 1.6M
- Earning Date
- ACAD 08-06-2025
- SEE 08-05-2025
- Dividend Yield
- ACAD N/A
- SEE N/A
- EPS Growth
- ACAD 615.00
- SEE N/A
- EPS
- ACAD 1.33
- SEE 1.98
- Revenue
- ACAD $1,018,885,000.00
- SEE $5,325,400,000.00
- Revenue This Year
- ACAD $14.01
- SEE N/A
- Revenue Next Year
- ACAD $11.72
- SEE $1.94
- P/E Ratio
- ACAD $19.61
- SEE $15.97
- Revenue Growth
- ACAD 14.41
- SEE N/A
- 52 Week Low
- ACAD $13.40
- SEE $22.78
- 52 Week High
- ACAD $26.65
- SEE $38.85
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- SEE 60.02
- Support Level
- ACAD $25.14
- SEE $31.81
- Resistance Level
- ACAD $26.65
- SEE $32.97
- Average True Range (ATR)
- ACAD 0.67
- SEE 0.79
- MACD
- ACAD 0.04
- SEE 0.21
- Stochastic Oscillator
- ACAD 70.27
- SEE 82.38
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.